Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

FDA approves Teva drug

Jan. 31, 1997

FDA approves antidiabetic drug within 6 months of filing

Jan. 31, 1997

Biotech launches Diab II

Jan. 31, 1997

Shaman describes antidiabetic agents from natural source

Jan. 31, 1997

Takeda researches follow-up compounds to leuprorelin

Jan. 31, 1997

Mixed CCK-A agonist/CCK-B antagonist from Glaxo Wellcome

Jan. 30, 1997

NutraGenics changes name, receives patent coverage for proprietary technology

Jan. 30, 1997

Pfizer reveals agents for hypercholesterolemia, atherosclerosis

Jan. 30, 1997

Antisense compound targeting cholesterol reported

Jan. 29, 1997

MK-677 enhances GH activity in the elderly

Jan. 29, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...